These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 29938225)

  • 1. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.
    Durant ST; Zheng L; Wang Y; Chen K; Zhang L; Zhang T; Yang Z; Riches L; Trinidad AG; Fok JHL; Hunt T; Pike KG; Wilson J; Smith A; Colclough N; Reddy VP; Sykes A; Janefeldt A; Johnström P; Varnäs K; Takano A; Ling S; Orme J; Stott J; Roberts C; Barrett I; Jones G; Roudier M; Pierce A; Allen J; Kahn J; Sule A; Karlin J; Cronin A; Chapman M; Valerie K; Illingworth R; Pass M
    Sci Adv; 2018 Jun; 4(6):eaat1719. PubMed ID: 29938225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice.
    Karlin J; Allen J; Ahmad SF; Hughes G; Sheridan V; Odedra R; Farrington P; Cadogan EB; Riches LC; Garcia-Trinidad A; Thomason AG; Patel B; Vincent J; Lau A; Pike KG; Hunt TA; Sule A; Valerie NCK; Biddlestone-Thorpe L; Kahn J; Beckta JM; Mukhopadhyay N; Barlaam B; Degorce SL; Kettle J; Colclough N; Wilson J; Smith A; Barrett IP; Zheng L; Zhang T; Wang Y; Chen K; Pass M; Durant ST; Valerie K
    Mol Cancer Ther; 2018 Aug; 17(8):1637-1647. PubMed ID: 29769307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis.
    Tew BY; Kalfa AJ; Yang Z; Hurth KM; Simon T; Abnoosian E; Durant ST; Hamerlik P; Salhia B
    Clin Cancer Res; 2023 Nov; 29(21):4492-4503. PubMed ID: 37585496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors.
    Talele S; Zhang W; Chen J; Gupta SK; Burgenske DM; Sarkaria JN; Elmquist WF
    J Pharmacol Exp Ther; 2022 Oct; 383(1):91-102. PubMed ID: 36137710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR Screen of Druggable Targets in Small Cell Lung Cancer Identified ATM Inhibitor (AZD1390) as a Radiosensitizer.
    Ran X; Wu BX; Shi M; Song L; Nixon K; Philip V; He HH; Tsao MS; Lok BH
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1308-1314. PubMed ID: 38104868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study.
    Jucaite A; Stenkrona P; Cselényi Z; De Vita S; Buil-Bruna N; Varnäs K; Savage A; Varrone A; Johnström P; Schou M; Davison C; Sykes A; Pilla Reddy V; Hoch M; Vazquez-Romero A; Moein MM; Halldin C; Merchant MS; Pass M; Farde L
    Neuro Oncol; 2021 Apr; 23(4):687-696. PubMed ID: 33123736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATM inhibition enhances the efficacy of radiation across distinct molecular subgroups of pediatric high-grade glioma.
    Xie J; Kuriakose T; Bianski B; Twarog N; Savage E; Xu K; Zhu X; He C; Hansen B; Wang H; High A; Li Y; Rehg JE; Tillman HS; Freeman BB; Rankovic Z; Onar-Thomas A; Fan Y; Wu G; Peng J; Miller S; Baker SJ; Shelat AA; Tinkle CL
    Neuro Oncol; 2023 Oct; 25(10):1828-1841. PubMed ID: 36971093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.
    Hickson I; Zhao Y; Richardson CJ; Green SJ; Martin NM; Orr AI; Reaper PM; Jackson SP; Curtin NJ; Smith GC
    Cancer Res; 2004 Dec; 64(24):9152-9. PubMed ID: 15604286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation.
    Biddlestone-Thorpe L; Sajjad M; Rosenberg E; Beckta JM; Valerie NC; Tokarz M; Adams BR; Wagner AF; Khalil A; Gilfor D; Golding SE; Deb S; Temesi DG; Lau A; O'Connor MJ; Choe KS; Parada LF; Lim SK; Mukhopadhyay ND; Valerie K
    Clin Cancer Res; 2013 Jun; 19(12):3189-200. PubMed ID: 23620409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization.
    Chen J; Laverty DJ; Talele S; Bale A; Carlson BL; Porath KA; Bakken KK; Burgenske DM; Decker PA; Vaubel RA; Eckel-Passow JE; Bhargava R; Lou Z; Hamerlik P; Harley B; Elmquist WF; Nagel ZD; Gupta SK; Sarkaria JN
    Sci Transl Med; 2024 Feb; 16(734):eadj5962. PubMed ID: 38354228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
    Cui Y; Palii SS; Innes CL; Paules RS
    Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.
    Gil del Alcazar CR; Hardebeck MC; Mukherjee B; Tomimatsu N; Gao X; Yan J; Xie XJ; Bachoo R; Li L; Habib AA; Burma S
    Clin Cancer Res; 2014 Mar; 20(5):1235-48. PubMed ID: 24366691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma.
    Laverty DJ; Gupta SK; Bradshaw GA; Hunter AS; Carlson BL; Calmo NM; Chen J; Tian S; Sarkaria JN; Nagel ZD
    Nat Commun; 2024 Jun; 15(1):5294. PubMed ID: 38906885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin-mediated radiosensitization of non-small cell lung cancer cells is stimulated by ATM inhibition.
    Toulany M; Mihatsch J; Holler M; Chaachouay H; Rodemann HP
    Radiother Oncol; 2014 May; 111(2):228-36. PubMed ID: 24857596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion.
    Golding SE; Rosenberg E; Valerie N; Hussaini I; Frigerio M; Cockcroft XF; Chong WY; Hummersone M; Rigoreau L; Menear KA; O'Connor MJ; Povirk LF; van Meter T; Valerie K
    Mol Cancer Ther; 2009 Oct; 8(10):2894-902. PubMed ID: 19808981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS Tumors.
    Rathi S; Mladek AC; Oh JH; Dragojevic S; Burgenske DM; Zhang W; Talele S; Zhang W; Bakken KK; Carlson BL; Connors MA; He L; Hu Z; Sarkaria JN; Elmquist WF
    J Pharmacol Exp Ther; 2024 Oct; 391(2):346-360. PubMed ID: 39284626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response.
    Huang CY; Hsieh FS; Wang CY; Chen LJ; Chang SS; Tsai MH; Hung MH; Kuo CW; Shih CT; Chao TI; Chen KF
    Eur J Cancer; 2018 Oct; 102():10-22. PubMed ID: 30103095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and toxicity of ATM inhibition in glioblastoma initiating cells-driven tumor models.
    Frosina G; Marubbi D; Marcello D; Vecchio D; Daga A
    Crit Rev Oncol Hematol; 2019 Jun; 138():214-222. PubMed ID: 31092378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BIBR1532, a Selective Telomerase Inhibitor, Enhances Radiosensitivity of Non-Small Cell Lung Cancer Through Increasing Telomere Dysfunction and ATM/CHK1 Inhibition.
    Ding X; Cheng J; Pang Q; Wei X; Zhang X; Wang P; Yuan Z; Qian D
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):861-874. PubMed ID: 31419512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
    Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
    Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.